Amarin Corp Plc (AMRN)

[Whalatane]

Alm2. Good to see U posting again

My guess is that Denner will try and prepare AMRN for the best BO price possible by the end of 2023
Reasons

Covid likely to have less of an impact on MD / patient engagement , willingness to get blood draws / lipid panels by then

AMRN will have all the reimbursement specifics in all the significant EU markets

AMRN will have had roughly 1 year to aggressively try to get 10 % of the EU / UK reimbursed market on Vazkepa

Cash on hand will be significantly lower by
end of 2023 because of cost of an aggressive launch in the EU / UK … so Co may face choice of a capital raise or a sale …a decision they aren’t facing now

Time left on the EU exclusivity clock

Hopefully a settlement or decision in the HealthNet case which would affect value of US market by late 2023
Do U have any thoughts on if this case is likely to be settled before mid/ late 2023 trial ?

Kiwi